You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

Bexagliflozin - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for bexagliflozin and what is the scope of patent protection?

Bexagliflozin is the generic ingredient in one branded drug marketed by Theracosbio and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bexagliflozin has seventy-one patent family members in thirty-two countries.

Two suppliers are listed for this compound.

Summary for bexagliflozin
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bexagliflozin
Generic Entry Date for bexagliflozin*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for bexagliflozin

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
TheracosPhase 2/Phase 3
TheracosPhase 1
TheracosPhase 3

See all bexagliflozin clinical trials

Pharmacology for bexagliflozin

US Patents and Regulatory Information for bexagliflozin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theracosbio BRENZAVVY bexagliflozin TABLET;ORAL 214373-001 Jan 20, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Theracosbio BRENZAVVY bexagliflozin TABLET;ORAL 214373-001 Jan 20, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Theracosbio BRENZAVVY bexagliflozin TABLET;ORAL 214373-001 Jan 20, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Theracosbio BRENZAVVY bexagliflozin TABLET;ORAL 214373-001 Jan 20, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Theracosbio BRENZAVVY bexagliflozin TABLET;ORAL 214373-001 Jan 20, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Theracosbio BRENZAVVY bexagliflozin TABLET;ORAL 214373-001 Jan 20, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for bexagliflozin

Country Patent Number Title Estimated Expiration
Mexico 2012014423 FORMA CRISTALINA DE BENCILBENCENO INHIBIDOR DE SGLT2. (CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR.) ⤷  Sign Up
China 101790311 Benzylbenzene derivatives and methods of use ⤷  Sign Up
Colombia 6640246 Forma cristalina del inhibidor sglt2 bencilbenceno ⤷  Sign Up
Argentina 068016 DERIVADOS DE BENCILBENCENO, UNA COMPOSICION FARMACEUTICA QUE LOS COMPRENDE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR SGLT ⤷  Sign Up
Taiwan I589295 ⤷  Sign Up
Poland 2187742 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.